StreetInsider.com News Articles

Form 8-K CervoMed Inc. For: Oct 14

Wed, 14 Oct 2026 16:05:00 -0400

si-local-file:///var/storage/secattach/20261014/27187136.html

Form 8-K CervoMed Inc. For: Oct 12

Tue, 13 Oct 2026 08:36:00 -0400

si-local-file:///var/storage/secattach/20261013/27177926.html

CervoMed reports early biomarker data from nfvPPA drug trial

Mon, 12 Oct 2026 07:30:18 -0400

CervoMed Inc. (NASDAQ: CRVO) announced initial 12-week biomarker results from its Phase 2a clinical trial of neflamapimod in nonfluent variant primary progressive aphasia (nfvPPA), showing a mean reduction in plasma neurofilament light chain (NfL) levels among participants during the open-label treatment period.

The data were presented at the 15th International Society of Frontotemporal Dementias Annual Meeting in Philadelphia. The trial enrolled 25 participants across academic medical centers in the United States and United Kingdom.

At baseline, 72% of participants had elevated NfL levels relative to the general population, with a mean baseline NfL of 45.7 pg/mL. Over the first 12 weeks, mean

CervoMed Presents Initial Results of Phase 2a Trial of Neflamapimod in Nonfluent Variant Primary Progressive Aphasia (nfvPPA) Showing Positive Effects on a Key Neurodegeneration Biomarker in Late-Brea

Mon, 12 Oct 2026 07:30:00 -0400

On average, reduction in plasma neurofilament light levels was observed during the first 12 weeks of treatment, with a greater decline in participants with baseline levels at or above the median

24-week biomarker data to be presented at the Clinical Trials on Alzheimer’s Disease in November 2026; clinical data expected in the first quarter of 2027

nfvPPA, the form of frontotemporal dementia most commonly associated with tau pathology, has no approved treatments in the United States or European Union

BOSTON, Oct. 12, 2026 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO) (CervoMed or

CervoMed Presents Initial Results of Phase 2a Trial of Neflamapimod in Nonfluent Variant Primary Progressive Aphasia (nfvPPA) Showing Positive Effects on a Key Neurodegeneration Biomarker in Late-Brea

Mon, 12 Oct 2026 07:30:00 -0400

On average, reduction in plasma neurofilament light levels was observed during the first 12 weeks of treatment, with a greater decline in participants with baseline levels at or above the median

24-week biomarker data to be presented at the Clinical Trials on Alzheimer’s Disease in November 2026; clinical data expected in the first quarter of 2027

nfvPPA, the form of frontotemporal dementia most commonly associated with tau pathology, has no approved treatments in the United States or European Union

BOSTON, Oct. 12, 2026 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO) (CervoMed or

Form 8-K CervoMed Inc. For: Oct 09

Fri, 09 Oct 2026 16:06:00 -0400

si-local-file:///var/storage/secattach/20261009/27171588.html

H.C. Wainwright Reiterates Buy Rating on CervoMed (CRVO)

Mon, 05 Oct 2026 06:52:24 -0400

H.C. Wainwright analyst Raghuram Selvaraju reiterated a Buy rating and $25.00 price target on CervoMed (NASDAQ: CRVO).

The analyst commented: "Late last month, CervoMed announced pharmacokinetic (PK), regulatory, and manufacturing advances that enable a higher-dose, twice-daily (BID) oral regimen of neflamapimod in future clinical trials. The developments include a new neflamapimod 50mg oral tablet formulation with a PK profile favorable for twice-daily dosing, the FDA's removal of the previous plasma drug exposure limit, and the implementation of a controlled manufacturing process designed to support reproducible, large-scale tablet production. The new 50mg tablet contains the most stable crystalline form of neflamapimod, addressing

Form 8-K CervoMed Inc. For: Sep 28

Mon, 28 Sep 2026 17:07:00 -0400

si-local-file:///var/storage/secattach/20260928/27115416.html

CervoMed reports new neflamapimod tablet data, FDA lifts exposure cap

Mon, 28 Sep 2026 07:32:01 -0400

CervoMed Inc. (NASDAQ: CRVO) announced pharmacokinetic results for a new 50 mg oral tablet formulation of neflamapimod and said the U.S. Food and Drug Administration has removed a prior plasma drug exposure limit that had constrained dosing in clinical trials.

The new tablet formulation showed approximately 20% lower peak plasma concentration and approximately 20% higher plasma trough concentration 12 hours after dosing compared with the prior 40 mg capsule used in the Phase 2b RewinD-LB study. The company said the new formulation uses the most stable crystalline form of neflamapimod, addressing manufacturing variability observed with the earlier capsule.

The FDA's decision to

CervoMed Announces Pharmacokinetic Results with New Neflamapimod Oral Tablet Formulation and Secures FDA Removal of Drug Exposure Limit

Mon, 28 Sep 2026 07:30:00 -0400

New 50 mg tablet formulation delivers an improved pharmacokinetic profile and enables greater exposure and patient convenience

FDA removal of the prior drug exposure limit provides greater dosing flexibility in
future clinical trials

CervoMed plans to advance a 100 mg twice-daily regimen expected to achieve higher plasma trough drug concentrations than those associated with clinical activity in prior trials

BOSTON, Sept. 28, 2026 (GLOBE NEWSWIRE) -- CervoMed Inc. ("CervoMed" or the "Company") (NASDAQ: CRVO), a clinical-stage biotechnology company developing treatments for age-related brain disorders, today announced pharmacokinetic (PK), regulatory, and manufacturing

CervoMed Announces Pharmacokinetic Results with New Neflamapimod Oral Tablet Formulation and Secures FDA Removal of Drug Exposure Limit

Mon, 28 Sep 2026 07:30:00 -0400

New 50 mg tablet formulation delivers an improved pharmacokinetic profile and enables greater exposure and patient convenience

FDA removal of the prior drug exposure limit provides greater dosing flexibility in
future clinical trials

CervoMed plans to advance a 100 mg twice-daily regimen expected to achieve higher plasma trough drug concentrations than those associated with clinical activity in prior trials

CervoMed to Participate in the 5th Annual ROTH Healthcare Opportunities Conference

Tue, 22 Sep 2026 07:30:00 -0400

BOSTON, Sept. 22, 2026 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical stage company focused on developing treatments for age-related neurologic disorders (CervoMed or the Company), today announced that Company management will participate in a panel discussion and one-on-one meetings at the upcoming 5th Annual ROTH Healthcare Opportunities Conference being held in New York, NY, on Tuesday, September 29, 2026.

Panel Details
Title: "Frontiers in Neuroscience"
Date: Tuesday, September 29, 2026
Time: 10:00 AM – 10:50 AM ET

This panel will not be webcast. A recording of the panel will be available following the conference.

CervoMed to Participate in the 5th Annual ROTH Healthcare Opportunities Conference

Tue, 22 Sep 2026 07:30:00 -0400

Panel Details
Title: "Frontiers in Neuroscience"
Date: Tuesday, September 29, 2026
Time: 10:00 AM – 10:50 AM ET

This panel will not be webcast. A recording of the panel will be available following the conference.

Form 8-K CervoMed Inc. For: Sep 10

Thu, 10 Sep 2026 16:08:00 -0400

si-local-file:///var/storage/secattach/20260910/27048449.html

CervoMed nfvPPA trial data to be presented at ISFTD meeting

Thu, 10 Sep 2026 07:30:35 -0400

CervoMed Inc. (NASDAQ: CRVO) announced that initial biomarker results from its Phase 2a clinical trial of neflamapimod in nonfluent variant primary progressive aphasia (nfvPPA) have been accepted as a late-breaking oral presentation at the International Society of Frontotemporal Dementias (ISFTD) Annual Meeting in Philadelphia, Pennsylvania, scheduled for October 8-11, 2026.

The presentation, placed in the Plenary 6 "Hot Topics" session on October 11, 2026, will highlight 12-week data for two plasma biomarkers — neurofilament light chain (NfL) and glial fibrillary acidic protein (GFAP) — from at least 22 of the trial's 25 enrolled participants. The abstract submitted for acceptance described data

CervoMed Announces Initial Results from the Phase 2a Clinical Trial of Neflamapimod in Nonfluent Variant Primary Progressive Aphasia (nfvPPA) Have Been Accepted as a Late-Breaking Oral Session at ISFT

Thu, 10 Sep 2026 07:30:00 -0400

12-week biomarker data to be highlighted at the International Society of Frontotemporal Dementias (ISFTD) Annual Meeting

nfvPPA, the type of frontotemporal dementia (FTD) most commonly associated with tau pathology, currently has no approved treatments in the United States or European Union

BOSTON, Sept. 10, 2026 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical-stage biotechnology company developing treatments for age-related brain disorders, today announced that neflamapimod, an oral, small molecule, drug candidate targeting critical disease processes underlying degenerative disorders of the brain, will be featured in a late-breaking oral presentation at the International Society of

CervoMed Announces Initial Results from the Phase 2a Clinical Trial of Neflamapimod in Nonfluent Variant Primary Progressive Aphasia (nfvPPA) Have Been Accepted as a Late-Breaking Oral Session at ISFT

Thu, 10 Sep 2026 07:30:00 -0400

12-week biomarker data to be highlighted at the International Society of Frontotemporal Dementias (ISFTD) Annual Meeting

nfvPPA, the type of frontotemporal dementia (FTD) most commonly associated with tau pathology, currently has no approved treatments in the United States or European Union

CervoMed to Participate in September Investor Conferences

Tue, 08 Sep 2026 07:30:00 -0400

BOSTON, Sept. 08, 2026 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical-stage biotechnology company developing treatments for age-related brain disorders ("CervoMed" or the "Company"), today announced that Company management will participate in the following investor conferences during the month of September:

Cantor Global Healthcare Conference
Format: Fireside Chat & 1x1 Investor Meetings
Date: Friday, September 11, 2026
Time: 10:55 – 11:25 AM ET

Webcast Link:
https://sqps.onstreamsecure.com/origin/enliven/players/EnlivenPlayer.html?customerId=22&eventId=43787678&checkCompany=1&checkEmail=1&checkName=1

H.C. Wainwright Global Investment Conference
Format: Presentation & 1x1 Investor Meetings
Date: Tuesday, September 15, 2026
Time: 4:00 – 4:30 PM ET

Webcast Link:

CervoMed to Participate in September Investor Conferences

Tue, 08 Sep 2026 07:30:00 -0400

Cantor Global Healthcare Conference
Format: Fireside Chat & 1x1 Investor Meetings
Date: Friday, September 11, 2026
Time: 10:55 – 11:25 AM ET

Webcast Link:
https://sqps.onstreamsecure.com/origin/enliven/players/EnlivenPlayer.html?customerId=22&eventId=43787678&checkCompany=1&checkEmail=1&checkName=1

H.C. Wainwright Global Investment Conference
Format: Presentation & 1x1 Investor Meetings
Date: Tuesday, September 15, 2026
Time: 4:00 – 4:30 PM ET

Webcast Link:

Form SCHEDULE 13G/A CervoMed Inc. Filed by: RA CAPITAL MANAGEMENT, L.P.

Fri, 14 Aug 2026 16:48:00 -0400

si-local-file:///var/storage/secattach/20260814/26932117.html

Form SCHEDULE 13G/A CervoMed Inc. Filed by: RA CAPITAL MANAGEMENT, L.P.

Fri, 14 Aug 2026 16:48:00 -0400

si-local-file:///var/storage/secattach/20260814/26932117.html

Form SCHEDULE 13G/A CervoMed Inc. Filed by: CVI Investments, Inc.

Fri, 14 Aug 2026 14:42:00 -0400

si-local-file:///var/storage/secattach/20260814/26929129.html

Form SCHEDULE 13G/A CervoMed Inc. Filed by: CVI Investments, Inc.

Fri, 14 Aug 2026 14:42:00 -0400

si-local-file:///var/storage/secattach/20260814/26929129.html

Form SCHEDULE 13G CervoMed Inc. Filed by: Woodline Partners LP

Fri, 14 Aug 2026 11:03:00 -0400

si-local-file:///var/storage/secattach/20260814/26927031.html

Form SCHEDULE 13G CervoMed Inc. Filed by: Woodline Partners LP

Fri, 14 Aug 2026 11:03:00 -0400

si-local-file:///var/storage/secattach/20260814/26927031.html